Treace Medical price target lowered to $2 from $3 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Treace Medical (TMCI) to $2 from $3 and keeps a Hold rating on the shares. The company’s Q4 saw negative mix shift impact related to new product launches and lower sales percent of Treace’s higher average sales price lapiplasty offering, the analyst tells investors in a research note. Truist adds that it remains on hold pending greater confidence that new rollouts can re-accelerate growth back into positive territory.